In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.
In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.
Constantine Tam, MD, MBBS, discusses the clinical results from the phase 3 ASPEN trial that led to the approval of zanubrutinib for the treatment of adult patients with WM.
Constantine Tam, MD, MBBS, discusses the clinical results from the phase 3 ASPEN trial that led to the approval of zanubrutinib for the treatment of adult patients with WM.
Steven Treon, MD, PhD, and Christian Buske, MD, discuss recent data surrounding the use of rituximab maintenance for patients with Waldenström macroglobulinemia.
Steven Treon, MD, PhD, and Christian Buske, MD, discuss recent data surrounding the use of rituximab maintenance for patients with Waldenström macroglobulinemia.
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...